AU-13462

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameAU-13462

Drug Alias Namedual PD-L1 checkpoint inhibitor/TIGIT checkpoint inhibitor (Aurigene Discovery Technologies)immune checkpoint pathway modulators (Aurigene Discovery Technologies)AU-13462AUBHA-13462

ClassificationSmall molecules

Mechanisms of ActionProgrammed death-ligand 1 blockersT lymphocytes stimulantsT cell immunoglobulin and ITIM domains inhibitors +[4]

TargetsProgrammed death-ligand 1T cell immunoglobulin and ITIM domains

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAurigene Oncology Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAurigene Oncology Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A